| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2014PLoSO...9k2394O |
| P356 | DOI | 10.1371/JOURNAL.PONE.0112394 |
| P932 | PMC publication ID | 4234367 |
| P698 | PubMed publication ID | 25402275 |
| P5875 | ResearchGate publication ID | 268449747 |
| P50 | author | Serge P Bottari | Q57193423 |
| Andreas Daiber | Q85386666 | ||
| P2093 | author name string | Thomas Münzel | |
| Thomas Jansen | |||
| Eric Mayoux | |||
| Anna Gottschlich | |||
| Eberhard Schulz | |||
| Elena Zinßius | |||
| Matthias Oelze | |||
| Michael Hausding | |||
| Michael Mader | |||
| Paul Stamm | |||
| Philipp Welschof | |||
| Saule Agdauletova | |||
| Sebastian Steven | |||
| Swenja Kröller-Schön | |||
| Yuliya Mikhed | |||
| P2860 | cites work | Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes | Q22250887 |
| Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart | Q24656840 | ||
| Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy | Q28266524 | ||
| Mitochondrial redox signaling: Interaction of mitochondrial reactive oxygen species with other sources of oxidative stress | Q28660732 | ||
| Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage | Q29616101 | ||
| Mechanisms underlying endothelial dysfunction in diabetes mellitus | Q31829307 | ||
| Deposition of advanced glycation end products (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat. | Q31984646 | ||
| Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet | Q33857698 | ||
| Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. | Q33929661 | ||
| Identification of the enzymatic mechanism of nitroglycerin bioactivation | Q34032459 | ||
| Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors | Q34222752 | ||
| Glutathione peroxidase-1 deficiency potentiates dysregulatory modifications of endothelial nitric oxide synthase and vascular dysfunction in aging. | Q34389247 | ||
| Role of reduced lipoic acid in the redox regulation of mitochondrial aldehyde dehydrogenase (ALDH-2) activity. Implications for mitochondrial oxidative stress and nitrate tolerance | Q34581407 | ||
| Multiple antioxidants improve cardiac complications and inhibit cardiac cell death in streptozotocin-induced diabetic rats | Q34812355 | ||
| Vascular dysfunction in experimental diabetes is improved by pentaerithrityl tetranitrate but not isosorbide-5-mononitrate therapy | Q35227188 | ||
| Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications | Q35661794 | ||
| Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. | Q51326175 | ||
| Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. | Q54351740 | ||
| Respiratory burst activity of monocytes from patients with non-insulin-dependent diabetes mellitus | Q70977950 | ||
| Roles of the AGE-RAGE system in vascular injury in diabetes | Q73921976 | ||
| Vascular dysfunction in streptozotocin-induced experimental diabetes strictly depends on insulin deficiency | Q83314291 | ||
| Chromatographic determination of methyl glyoxal in blood plasma as the test for glycotoxicity and accumulation of glycation end-products | Q84584528 | ||
| Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition | Q84658993 | ||
| Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects | Q85428079 | ||
| The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat | Q88214242 | ||
| A lethal tetrad in diabetes: hyperglycemia, dyslipidemia, oxidative stress, and endothelial dysfunction | Q36311819 | ||
| Number of nitrate groups determines reactivity and potency of organic nitrates: a proof of concept study in ALDH-2-/- mice | Q36357767 | ||
| Oxidative stress and diabetic cardiovascular complications | Q36368516 | ||
| Nicotinamide effects oxidative burst activity of neutrophils in patients with poorly controlled type 2 diabetes mellitus | Q36812506 | ||
| RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. | Q37146417 | ||
| Molecular mechanisms of the crosstalk between mitochondria and NADPH oxidase through reactive oxygen species-studies in white blood cells and in animal models. | Q37460376 | ||
| Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients | Q37524302 | ||
| The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus | Q37559421 | ||
| Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. | Q37575461 | ||
| Effects of sildenafil on oxidative and inflammatory injuries of the kidney in streptozotocin-induced diabetic rats | Q38498729 | ||
| Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. | Q40238396 | ||
| Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. | Q40483773 | ||
| Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates the coupling of L-arginine metabolism to efficient nitric oxide production | Q40638231 | ||
| Aging and insulin resistance: just say iNOS. | Q41860198 | ||
| Regulation of human mitochondrial aldehyde dehydrogenase (ALDH-2) activity by electrophiles in vitro | Q41932170 | ||
| Angiotensin II impairs endothelial function via tyrosine phosphorylation of the endothelial nitric oxide synthase | Q42463456 | ||
| Inhibition of Aldehyde Dehydrogenase 2 by Oxidative Stress Is Associated with Cardiac Dysfunction in Diabetic Rats | Q42701033 | ||
| Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. | Q43565214 | ||
| Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy | Q44195281 | ||
| Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus | Q44418300 | ||
| Oxidative stress in diabetes-induced endothelial dysfunction involvement of nitric oxide and protein kinase C. | Q44574884 | ||
| Oxidative stress and mitochondrial aldehyde dehydrogenase activity: a comparison of pentaerythritol tetranitrate with other organic nitrates | Q45032651 | ||
| AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats | Q46551832 | ||
| CD40L contributes to angiotensin II-induced pro-thrombotic state, vascular inflammation, oxidative stress and endothelial dysfunction | Q46991200 | ||
| A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes | Q47916425 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | empagliflozin | Q5373824 |
| P304 | page(s) | e112394 | |
| P577 | publication date | 2014-11-17 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity | |
| P478 | volume | 9 |
| Q38537119 | A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans |
| Q40051780 | A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats. |
| Q41855979 | Acute blood glucose fluctuation enhances rat aorta endothelial cell apoptosis, oxidative stress and pro-inflammatory cytokine expression in vivo |
| Q92722913 | Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence |
| Q89893743 | Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice |
| Q90512283 | Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice |
| Q54119005 | Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. |
| Q39425969 | Carbonyl stress phenomena during chronic infection with Opisthorchis felineus. |
| Q47297477 | Cardioprotective anti-hyperglycaemic medications: a review of clinical trials |
| Q37620904 | Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes |
| Q49343999 | Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. |
| Q64100428 | Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice |
| Q55405814 | Comparison of Pulmonary and Systemic NO- and PGI2-Dependent Endothelial Function in Diabetic Mice. |
| Q42643495 | Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study |
| Q59813541 | Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients |
| Q93000206 | Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice |
| Q49716961 | Effect of glucose-lowering therapies on heart failure |
| Q90290631 | Effectiveness of sodium-glucose co-transporter-2 inhibitors on ischaemic heart disease |
| Q92993277 | Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus |
| Q37325818 | Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes |
| Q49423096 | Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects. |
| Q89763523 | Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat |
| Q55384960 | Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts. |
| Q89537944 | Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence |
| Q40249782 | Formation of 2-nitrophenol from salicylaldehyde as a suitable test for low peroxynitrite fluxes |
| Q41579741 | Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse |
| Q92100799 | How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical concept and methodology |
| Q64101440 | How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial |
| Q89123166 | Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress |
| Q59807260 | Improvement of Diabetes Mellitus Symptoms by Intake of Ninjin'yoeito |
| Q41227936 | Insulin stimulates SGLT2-mediated tubular glucose absorption via oxidative stress generation |
| Q89506074 | Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors |
| Q88142916 | Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study |
| Q89384709 | Resveratrol shows neuronal and vascular-protective effects in older, obese, streptozotocin-induced diabetic rats |
| Q38855635 | Reversibility of endothelial dysfunction in diabetes: role of polyphenols |
| Q90446487 | SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review |
| Q37586729 | Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes |
| Q28072765 | Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects |
| Q64086648 | Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives |
| Q39140884 | Taking up the cudgels for the traditional reactive oxygen and nitrogen species detection assays and their use in the cardiovascular system. |
| Q38698841 | The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. |
| Q28082343 | The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure |
| Q47643546 | The adverse effects of environmental noise exposure on oxidative stress and cardiovascular risk. |
| Q38793748 | The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial |
| Q36301818 | The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis |
| Q38927264 | The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors |
| Q38990014 | Therapeutic Targeting of Cellular Stress to Prevent Cardiovascular Disease: A Review of the Evidence |
| Q41974803 | Uncoupling of Vascular Nitric Oxide Synthase Caused by Intermittent Hypoxia. |
| Q91301271 | Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases |
| Q92156078 | Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease |
Search more.